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Once vs. twice-daily lopinavir/ritonavir
in HIV-1-infected children
Paediatric European Network for Treatment of AIDS (PENTA)
Objective: To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to
twice daily (b.i.d.) dosing in children.
Design: International, multicentre, phase II/III, randomized, open-label, noninferiority
trial (KONCERT/PENTA18/ANRS150).
Setting: Clinical centres participating in the PENTA, HIV-NAT and PHPT networks.
Participants: Children/adolescents with HIV-1 RNA viral load less than 50 copies/ml
for at least 24 weeks on lopinavir/ritonavir-containing antiretroviral therapy.
Intervention: Children were randomized to continue lopinavir/ritonavir b.i.d. or
change to q.d.
Main outcome measure: Confirmed viral load 50 copies/ml by 48 weeks (12%
noninferiority margin).
Results: One hundred seventy-three children were randomized in the KONCERT trial
(86 q.d., 87 b.i.d.); 46% men, median (IQR) age 11 (9–14) years, CD4% 33 (27–38)%.
By week 48, 97 and 98% of time was spent on q.d. and b.i.d., respectively (one q.d.
child lost at week 4). Twelve q.d. vs. seven b.i.d. children had confirmed viral load
50 copies/ml within 48 weeks; estimated difference in percentage with viral load
rebound 6% [90% CI (–2, 14)]. Numbers of children with grade 3/4 adverse events (11
vs. 7) or major resistance mutations (3 vs. 2) were similar, q.d. vs. b.i.d. (both P > 0.3).
Among 26 children in an intrasubject lopinavir/ritonavir pharmacokinetic substudy,
lower daily exposure (AUC0–24 161 h.mg/l vs. 224 h.mg/l) and lower Clast (1.03mg/l vs.
5.69mg/l) were observed with q.d. vs. b.i.d. dosing.
Conclusion: Noninferiority for viral load suppression on q.d. vs. b.i.d. lopinavir/
ritonavir was not demonstrated. Although results, therefore, do not support routine
use of q.d. lopinavir/ritonavir, lack of safety concerns or resistance suggest that q.d.
dosing remains an option in selected, adherent children, with close viral load monitor-
ing. Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Antiretroviral drugs have changed HIV-1 infection from a
life-threatening disease to a chronic infection. However,
adherence to therapy remains a key determinant of disease
outcome. For perinatally HIV-infected children, who
face a lifetime on treatment, maintaining long-term
adherence is often a challenge. Simplification of
treatment, including decreasing the frequency of dosing,
is likely to increase convenience and enhance adherence
to antiretroviral therapy (ART) [1]. Although several q.d.
regimens have been shown to have noninferior efficacy
and safety in adults [2], resulting in Food and Drug
Administration (FDA) and European Medicines Agency
Clinical Trials Unit, University College London, London, UK.
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(EMA) approval and widespread use in clinical practice,
fewer antiretroviral drugs are licensed to be taken q.d. by
children.
Protease inhibitors are potential candidates for q.d.
dosing. They have a high genetic barrier to development
of resistance [3] and when coadministered with ritonavir,
resulting in increased absorption and/or prolonged
terminal elimination half-life, have increasing potential
for decreased dosing frequency. The coformulation of
ritonavir-boosted lopinavir (lopinavir/r) in one tablet
(also available as a smaller paediatric formulation) also
enhances convenience of dosing. Various studies have
supported the licensing of q.d. dosing of lopinavir/r for
HIV-infected adults [2,4–7]. However, based on the
currently available evidence in children, paediatric
treatment guidelines recommend lopinavir/r to be taken
twice daily (b.i.d.) [8,9]. Small studies using q.d.
lopinavir/r oral solution or soft gel capsules in children
showed high interpatient variability in lopinavir phar-
macokinetic parameters and low trough levels [10,11].
Reduced variability in lopinavir pharmacokinetic in
adults and children has been observed after administration
of the tablet formulation, suggesting that this formulation
could be more appropriate for q.d. dosing [12,13]. Here
we report the results of KONCERT (PENTA18/
ANRS150), the first randomized controlled trial eval-
uating the safety, efficacy and pharmacokinetic of
lopinavir/r tablets dosed q.d. vs. b.i.d. following FDA
body-weight band dosing guidelines in virologically
suppressed ART-experienced children and adolescents.
Methods
Study design and participants
KONCERTwas an open-label, multicentre, randomized
trial (ISRCTN02452400, EudraCT 2009-013648-35) in
HIV-infected children aged below 18 years who had a
stable CD4þ cell count on combination ART containing
b.i.d. lopinavir/r and had been virologically suppressed
(viral load <50 copies/ml) for at least 24 weeks (single
viral load <400 copies/ml allowed). In addition, eligi-
bility required that children had viral load less than
50 copies/ml at screening, weighed15 kg and were able
to swallow tablets. Kaletra tablets were used throughout.
If required, lopinavir/r dose was adjusted at screening in
line with the US FDA dosing guidelines based on body-
weight band [total daily dose: 400/100mg lopinavir/r (15
to 25 kg), 600/150mg (25 to 35 kg) or 800/200mg
(>35 kg)] [14]. Children were randomized 1 : 1 to
continue taking lopinavir/r b.i.d. or to take their total
daily lopinavir/r in a single dose. Parents/guardians and
adolescents provided written consent, younger children
gave assent according to their age and knowledge of HIV
status. The study received approval from ethics commit-
tees and regulatory bodies in each participating country
and clinical site.
Randomization was stratified by weight band (as above)
and participation in the pharmacokinetic substudy. The
computer-generated sequentially numbered randomiz-
ation list (with variable block sizes) was preprepared by
the trial statistician and securely incorporated within the
database at the Trials Unit. Randomization was under-
taken via a web service accessed by the clinician or Trials
Unit, who could access the next allocation but not the
whole list.
Outcome measures
The primary endpoint was a viral load at least 50 copies/
ml (confirmed within 4 weeks) within the first 48 weeks
of follow-up. Primary endpoints for the pharmacokinetic
substudies were pharmacokinetic parameters of lopina-
vir/r [area under the curve (AUC), Cmax, Clast] [1],
comparing b.i.d. (week 0) to historical pharmacokinetic
data, and [2] comparing q.d. (week 4) to b.i.d. (week 0) in
the same children. Analysis of endpoint [1] has previously
been described [15]. Secondary outcomes included the
following: viral load at least 400 copies/ml (confirmed)
within 48 weeks; number of major HIV-1 RNA
mutations in those with viral rebound; change in
CD4þ cell count/percentage from baseline to 48 weeks;
adherence to, acceptability of, and changes made to the
ART regimen; ART-related grades 3 and 4 clinical or
laboratory adverse events [16,17].
Data collection and follow-up procedures
Follow-up visits were scheduled at weeks 4, 8 and 12,
then 12 weekly until the last child reached week 48
(Fig. 1). Viral load was measured at each study visit;
children with viral load at least 50 copies/ml returned
within 4 weeks for retest of viral load. Assessment of
adherence to treatment and a resistance test were
requested when children had a confirmed viral load at
least 50 copies/ml. T-cell lymphocyte subsets were
performed at all visits; biochemistry and haematology
were performed 12-weekly; blood lipids were measured
at weeks 0, 24 and 48; adherence questionnaires were
given to carers and children at weeks 0, 4, 12, 24 and 48;
acceptability questionnaires were completed at baseline
and if children switched from q.d. to b.i.d. dosing. At each
study visit, a plasma sample was stored for subsequent
assessment of population lopinavir/r pharmacokinetic.
Pharmacokinetic substudy
Children who consented were enrolled in a pharmaco-
kinetic substudy, until a minimum of 16 children in each
stratification weight band had evaluable pharmacokinetic
data. Children with nonevaluable pharmacokinetic
results were followed within the main study, but excluded
from the pharmacokinetic analysis. Lopinavir pharma-
cokinetics were determined at week 0 in both arms, and
at week 4 if randomized to q.d. dosing. Prior to the day of
pharmacokinetic assessment, children took the paediatric
lopinavir/r tablet (100/25mg) formulation for at least
seven days, following the FDA-recommended weight
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band-based dosing. On the pharmacokinetic assessment
day, 2ml of blood was taken before observed intake of
lopinavir/r in the morning (t¼ 0) and at 2, 4, 6, 8 and 12
(week 0, b.i.d.) or 24 h (week 4, q.d.) after the dose.
Plasma concentrations were determined using a validated
ultrahigh performance liquid chromatography assay with
UV detection derived from a previously published assay
[18]. Lopinavir pharmacokinetic parameters were deter-
mined using noncompartmental analysis (WinNonlin/
Phoenix version 6.3; Pharsight Corporation, Mountain
View, California, USA): AUC0–24 [area under the plasma
concentration–time curve calculated (linear up-log down
method) over a dosing interval from time 0 to 24 h after
dosing], Cmax (maximum observed plasma concen-
tration), Tmax (time of maximum observed plasma
concentration), Clast (last observed drug concentration)
and clearance (CL/F). The intensive pharmacokinetic
analyses were performed at the Department of Pharmacy,
Radboud University Medical Center, Nijmegen, the
Netherlands.
Lopinavir concentrations were also determined on
available stored plasma samples at the screening visit and
at weeks 0, 4, 8, 12, 24, 36 and 48 on all children. This was
done to investigate the effect of having lopinavir plasma
concentration below the lower limit of quantification
(LLOQ¼ 0.10mg/l) at any visit on virological rebound.
Pharmacokinetic analyses for these stored samples were
performed at RadboudUniversityMedical Center, except
for samples in Thailand which were performed at the
PHPT-AMS laboratory, ChiangMai University, Thailand.
Both laboratories participate in an international inter-
laboratory quality control programme for therapeutic drug
monitoring of antiretroviral drugs [19].
KONCERT: once vs. twice daily LPV/r in children PENTA 2449
Excluded (n = 29)
¨ Not meeting inclusion criteria (n = 27)
¨ Declined to participate (n = 1)
¨ Other reasons (n = 1)
Analysed (n = 86) 
• Excluded from analysis (n = 0)
Lost to follow-up (n = 1)
• Patient moved to a different city (n = 1)
• Discontinued intervention (n = 4) 
• Switched to BID LPV/r (n = 3)
• Lost to follow-up (n = 1)
Allocated to QD LPV/r + 2NRTIs (n = 86)
• Received allocated intervention (n = 86)
¨ Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 3)
• Switched to QD LPV/r (n = 1)
• Switched to QD Darunavir (n = 2)
Allocated to BID LPV/r + 2NRTIs (n = 87)
¨ Received allocated intervention (n = 87) 
¨ Did not receive allocated intervention (n = 0)
Analysed (n = 87) 
• Excluded from analysis (n = 0)
Randomized (n = 173)
Assessed for eligibility (n = 202)
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Fig. 1. Trial profile. LPV, lopinavir; NRTI, nucleoside reverse-transcriptase inhibitor.
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Statistical analyses
A target enrolment of 160 children (80 in each arm)
provided at least 80% power to exclude a noninferiority
margin of 12% for the difference between the two arms in
the proportion of children reaching the primary end-
point, assuming a 10% virological rebound rate and one-
sided a¼ 0.05. An Independent Data Monitoring
Committee reviewed interim data for safety and efficacy
three times during the study.
All comparisons between randomized arms (q.d. vs. b.i.d.)
were intention-to-treat, with follow-up censored at
week 52 or last follow-up date (if before the week 48
visit). The proportion of children experiencing virological
rebound by week 48 in each arm was estimated using the
Kaplan–Meier method, with 90% confidence intervals
(CIs) for the difference in proportions calculated using
bootstrap standard errors [20]. Two prespecified sensitivity
analyses of theprimaryoutcomewere completed: adjusting
for baseline stratification factors, and censoring follow-up
at the time of lopinavir/r treatment modification (change
in dose, >7-day interruption or permanent discontinu-
ation; a ‘per-protocol’ analysis). A post-hoc analysis
adjusting for chance imbalance between arms in viral load
and CD4% at baseline was also performed.
Change in CD4% and other continuous laboratory
outcomes from baseline to 48 weeks were analyzed using
normal regression, adjusting for the baseline measure-
ment and stratification factors. Major resistance mutations
known to confer resistance to antiretroviral drugs not
seen in any pretrial resistance tests were summarized by
drug class. Categorical variables were compared using
Fisher’s exact tests; rates were estimated using Poisson
regression. All P values were two sided and all statistical
calculations were performed using STATA (Stata
Statistical Software, Release 13; StataCorp LP, College
Station, Texas, USA).
All paired evaluable pharmacokinetic assessments [on b.i.d.
(week 0) and q.d. (week 4)] in children randomized to q.d.
were included. Within subject ratios of AUC0–24,
clearance (Cl/F/kg), Cmax and Clast for q.d. vs. b.i.d.
dosing were calculated. AUC0–24 for b.i.d. dosing was
calculated as 2AUC0–12. An overall geometric mean ratio
(GMR) for each pharmacokinetic parameter was calcu-
lated after log-transformation of the within-subject ratios;
90% CIs were calculated (using the t-distribution) using
the bioequivalence crossover design tool approach
within the Phoenix WinNonlin software package (with
fixed effects in the model specification). A GMR with a
90%CI including 1.0 and falling entirelywithin 0.80–1.25
was considered as bioequivalence for AUC0–24 and
Cmax. Relative risk ratios were calculated comparing
the likelihood of virological rebound for children
with at least one sample with lopinavir concentration
levels below LLOQ to those children with all samples
 LLOQ.
Results
Baseline characteristics
Between August 2010 and August 2012, 173 children
were randomized (86 allocated to q.d., 87 to b.i.d.)
(Fig. 1); 80 children from Europe, 59 from Thailand and
34 from South America; participants were from 49
clinical centres in 12 countries. Fifty-three took part in
the pharmacokinetic substudy, 27 randomized to the q.d.
arm; 46, 50 and 77 children were in the 15 to 25kg, >25
to 35kg, >35kg weight bands, respectively.
Baseline demographics were similar in the two arms
(Table 1); median (IQR) age was 11.0 (8.7, 14.3) years
and 94 (54%) were female. More children in the q.d. arm
had advanced HIV disease, lower CD4% and a viral load
at least 50 copies/ml at baseline (Table 1). Pretrial ART
exposure was comparable between arms; 35 (20%)
children were on their first-line regimen at baseline,
and half had been exposed to three different antiretroviral
drug classes. The children were on a variety of NRTI
backbones at baseline (44% zidovudine þ lamivudine or
emtricitabine, 20% abacavir þ lamivudine or emtricita-
bine, 16% tenofovirþ any other NRTI, 20% other); 29%
of backbone NRTIs were taken as q.d. dosing (28% q.d.
arm, 30% b.i.d. arm); this proportion increased over the
time of the trial.
Follow-up and antiretroviral therapy received
One q.d. child withdrew consent at week 4; all other
children completed 48 weeks follow-up and are included
in all analyses. In total, 98 and 97% of follow-up time was
spent on q.d. and b.i.d. dosing of lopinavir/r in the q.d.
and b.i.d. arms, respectively. Twenty-nine (17%) children
made changes to their ARTregimen in the first 48 weeks
of follow-up [20 (23%) q.d., 9 (10%) b.i.d.]. In the q.d.
arm, two children switched back to b.i.d. lopinavir/r
dosing (at week 1 and 39), 17 children changed their
NRTI backbone (66% to q.d. regimens), and one child
did both at week 8. In the b.i.d. arm, one child switched
to q.d. lopinavir/r dosing at week 38 and eight children
changed their NRTI backbone.
Primary outcome
Nineteen children (12 q.d., seven b.i.d.) experienced
confirmed viral rebound at least 50 copies/ml during 48
weeks of follow-up; all but one rebound (q.d.) was
considered by the treating clinician to be adherence
related. The estimated percentage of children with viral
rebound by 48 weeks was 14% [95% CI (8, 24%)] in the
q.d. arm vs. 8% [(95% CI (4, 16%)] in the b.i.d. arm, an
estimated difference between arms of 6% [(90% CI (-2,
14%), bootstrap P¼ 0.19] (Fig. 2). The upper 90%
confidence limit of 14% was greater than the predefined
noninferiority margin of 12%.
Results were similar after adjustment for stratification
factors – estimated difference between arms of
2450 AIDS 2015, Vol 29 No 18
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6% [90% CI (–2%, 14%), bootstrap P¼ 0.20] – and for
per-protocol analyses wherein follow-up for eight
children was censored as a result of treatment modifi-
cation – estimated difference between arms of 5% [90%
CI (–3%, 13%), bootstrap P¼ 0.27]. A post-hoc analysis
adjusting for the chance imbalance between arms in viral
rebound at baseline, reduced the estimated difference in
proportion rebounding to 4% [90% CI (–4, 11%),
bootstrap P¼ 0.39], bringing the upper 90% confidence
limit just within the noninferiority margin.
Fifteen children [nine (75%) q.d., six (86%) b.i.d.]
remained on the same dosing regimen of lopinavir/r after
rebound, the majority of whom went on to resuppress
[seven (78%) q.d., four (67%) b.i.d.]. Two children (q.d.)
returned to b.i.d. dosing (one of whom resuppressed
during follow-up) and two (one q.d., one b.i.d.)
discontinued lopinavir/r after rebound (both resup-
pressed).
Secondary outcomes
Viral rebound defined as at least 400 copies/ml was
observed in 11 children (eight q.d., three b.i.d.); the
estimated difference between arms in the probability of
rebounding by 48 weeks was 6% [90% CI (0, 12%),
P¼ 0.10].
Genotypic resistance tests were available in 18 (12 q.d.,
6 b.i.d.) children with rebound within 48 weeks; major
new resistance-associated mutations were detected in five
(three q.d., two b.i.d.; one b.i.d. did not resupress
<50 copies/ml during follow-up). Major protease
inhibitor mutations were detected in none of the children
on q.d. vs. two children on b.i.d. lopinavir/r (L90M,
M46I þ V82A). The M184V mutation was detected in
one child from each arm; three children (two q.d., one
b.i.d.) had at least one thymidine-associated mutation.
Mean changes in CD4% from baseline to week 48 were
similar in both arms: 0.4% for the q.d. arm and 0.1% for
the b.i.d. arm [difference 0.3%, 95% CI (–1.0, 1.7%),
P¼ 0.61]. Changes in biochemistry, haematology and
lipid measurements were also minimal and comparable
(data not shown).
There were no new CDC stage C events or deaths
reported during the trial. Three new stage B events were
reported (two q.d.: pneumonia and herpes zoster; one
b.i.d.: cholecystitis).
There were no significant differences between the trial
arms for any of the clinical safety endpoints (Table 2).
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Fig. 2. Time to virological failure.
Table 1. Baseline characteristics.
Once daily Twice daily Total
Children randomized: n 86 87 173
Men: n (%) 41 (48) 38 (44) 79 (46)
Age (years): median (IQR) [range] 10.8 (8.7, 14.2) [4.3, 17.6] 11.2 (9.0, 14.5) [3.8, 17.7] 11.0 (8.7, 14.3) [3.8, 17.7]
Ethnic origin: n (%)
White 27 (31) 17 (20) 44 (25)
Black: African or other 17 (20) 29 (33) 46 (27)
Mixed black/white 5 (6) 6 (7) 11 (6)
Asian/Thai 31 (36) 30 (34) 61 (35)
Other 6 (7) 5 (6) 11 (6)
Vertically infected: n (%) 86 (100) 84 (97) 170 (98)
CDC stage: n (%)
N or A 28 (33) 39 (45) 67 (38)
B or C 58 (68) 48 (55) 106 (61)
Viral load (HIV-1 RNA) 50 copies/ml at randomizationa:
n (%) 12 (14) 4 (5) 16 (9)
Median [range] 120 [51, 91201] 135 [57, 270] 120 [51, 91201]
CD4%: mean (SD) 32.0 (6.5) 33.9 (8.6) 32.9 (7.7)
Weight (kg): median (IQR) 33.3 (24.6, 42.0) 32.2 (23.9, 43.8) 33.1 (24.6, 42.6)
[Range] [15.0, 72.5] [15.6, 68.9] [15.0, 72.5]
Baseline ART first regime: n (%) 18 (21) 17 (20) 35 (20)
Exposed to three classes of ART: n (%) 41 (48) 46 (53) 87 (50)
aAll <50 copies/ml at screening.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Fifteen serious adverse events in 14 children occurred
during the first 48 weeks of the trial [episodes (children):
nine q.d. [8], six b.i.d. [6], Fisher’s exact test: P¼ 0.6],
none of which were fatal or life threatening. All reported
serious adverse events were as a result of hospitalization;
only one event, diarrhoea reported during the first week
of the trial in a child taking q.d. lopinavir/r, was
considered possibly related to lopinavir/r by the treating
clinician. The incident risk ratio for q.d. relative to b.i.d.
was 1.72 [95% CI (0.63, 4.66), GEE Poisson regression
P¼ 0.29].
Twenty-two grade 3 or 4 clinical or laboratory adverse
events in 18 children were reported: [episodes (children):
13 [11] q.d., 9 [7] b.i.d., Fisher’s exact test: P¼ 0.3].
Three children experienced adverse events that led to
treatment modification: two children on q.d. with nausea
and vomiting changed back to b.i.d. dosing at weeks 1 and
8; one child on b.i.d. had neutropenia at week 4 and
substituted abacavir for zidovudine.
Both children and carers reported a preference for
q.d. dosage of lopinavir/r; 120 of 140 (86%) children
and 128 of 144 (89%) carers completing the accept-
ability questionnaire at trial enrolment thought q.d.
dosing would be easier than b.i.d. dosing. This
preference persisted at the end of trial, when 50 of
68 (74%) of children and 45 of 64 (70%) of carers
reported a preference. Combining responses to
adherence questionnaires completed by children or
carers at each trial visit during the first 48 weeks (89%
completion rate), missing a dose within 3 days of the
clinic visit was only reported on 20 occasions [14
(3.5%) q.d. vs. 6 (1.5%) b.i.d., GEE logistic regression:
P¼ 0.2].
Pharmacokinetic analysis
Intraindividual, paired comparison of lopinavir
twice-daily and once-daily dosing
Twenty-six out of 27 children randomized to the q.d. arm
in the pharmacokinetic substudy had evaluable full
pharmacokinetic at weeks 0 and 4. Table 3a and b shows
child demographic data and pharmacokinetic parameters
for lopinavir, respectively. Fifteen (58%) children on q.d.
dosing at week 4 compared with all children on b.i.d.
dosing at baseline had a Clast above 1.0mg/l, a
measurement associated with optimal virological response
in b.i.d. regimens [9]. The GMR (90% CI), q.d. vs. b.i.d.,
of lopinavir AUC0–24 and lopinavir Cmax were calculated
as 0.72 (0.62, 0.83) and 1.13 (1.00, 1.26), respectively.
Neither falling within the 80–125% limits required
for bioequivalence.
Routine measurement of lopinavir plasma
concentrations
Most children (76 q.d., 74 b.i.d.) had eight samples
available during the initial 48 weeks of follow-up for
determination of lopinavir plasma concentration (19
children had seven samples, 1 had six, 2 had five, 1 had
three). Overall, 28 (16.2%) children had at least one
lopinavir concentration that was below the LLOQ of
0.10mg/l: 21 (24.4%) q.d. vs. 7 (8.0%) b.i.d., Fisher’s
exact test P¼ 0.004. A higher proportion of children
reaching the primary endpoint of viral rebound had at
least one lopinavir plasma concentration <LLOQ [11
(57.9%) at least 1 sample <LLOQ vs. 8 (42.1%) no
samples <LLOQ: 9 q.d. 2 b.i.d., Fisher’s exact test
P¼ 0.03].
The overall relative risk (95% CI) of viral rebound,
stratified by randomized arm, given at least one lopinavir
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Table 2. Summary of adverse events to week 48 assessment.
Once-daily episodes
(children)
Twice-daily
episodes (children)
Total episodes
(children) P valueM
Total adverse events 271 (73) 232 (76) 503 (149) 0.7
Grades 1 and 2 adverse events 256 (70) 222 (76) 478 (146) 0.3
Grades 3 and 4 adverse events 13 (11) 9 (7) 22 (18) 0.3
Gastrointestinal disorders 2 (2) 2 (1) 4 (3) 1.0
Infections and infestations 4 (4) 3 (3) 7 (7) 0.7
Laboratory investigationsy 5 (4) 3 (2) 8 (6) 0.4
Blood and lymphatic system disorders 0 (0) 1 (1) 1 (1) 1.0
Hepatobiliary disorders 1 (1) 0 (0) 1 (1) 0.5
Nervous system disorders 1 (1) 0 (0) 1 (1) 0.5
Adverse events leading to treatment modification 4 (2) 1 (1) 5 (3) 0.6
Serious adverse events 9 (8) 6 (6) 15 (14) 0.6
Gastrointestinal disorders 2 (2) 1 (1) 3 (3) 0.6
Infections and infestations 5 (5) 4 (4) 9 (9) 0.75
Respiratory, thoracic and mediastinal disorders 0 (0) 1 (1) 1 (1) 1.0
Hepatobiliary disorders 1 (1) 0 (0) 1 (1) 0.5
Surgical and medical procedures 1 (1) 0 (0) 1 (1) 0.5
SAE rate per 100 person-years (95% CI) 9.5 (4.7, 19.0) 6.7 (3.0, 14.9) 8.0 (4.8, 13.6) 0.6MM
SAE, serious adverse event.
MFisher’s exact test.
MMPoisson regression.
yAbnormal laboratory values without reported associated clinical symptoms.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
concentration <LLOQ was 7.61 (2.95, 19.69). A trend
was observed of an increasing proportion experiencing
virological rebound when the number of samples with
concentrations<LLOQ increased: 5.5% with no samples
<LLOQ, 21.4% with one sample <LLOQ and 57.1%
with two or more samples <LLOQ.
Discussion
KONCERT is the first randomized controlled trial in
children and adolescents to investigate the safety and
efficacy of q.d. vs. b.i.d. dosing of lopinavir/r. Children
from a wide age-range were included, and all main ethnic
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Table 3. Within-children pharmacokinetic substudy in 26 children randomized to once-daily arm.
(a) Baseline characteristics
Weight band
15 to 25kg >25 to 35kg >35kg Total
Children: n 7 8 11 26
Men: n (%) 4 (57) 5 (63) 3 (27) 12 (46)
Age (years): median
(IQR) [range]
7.1 (6.7, 8.7)
[4.4, 8.9]
10.6 (9.5, 15.0)
[6.3, 16.0]
14.3 (13.5, 15.4)
[12.7, 16.8]
12.8 (8.7, 14.7)
[4.4, 16.8]
Weight (kg): median
(IQR) [range]
19.4 (19.0, 23.1)
[15.0, 24.1]
30.7 (29.8, 32.1)
[26.4, 33.8]
42.0 (38.5, 49.5)
[36.0, 72.5]
32.1 (24.1, 41.0)
[15.0, 72.5]
BMI (kg/m2): median
(IQR) [range]
15.1 (14.4, 15.7)
[11.5,15.8]
15.7 (14.8, 18.0)
[14.5, 19.4]
17.7 (17.4, 20.6)
[16.0, 27.6]
16.5 (15.1, 18.6)
[11.5, 27.6]
Vertically infected: n (%) 7 (100) 8 (100) 11 (100) 26 (100)
Ethnic origin: n (%)
White 0 (0) 1 (13) 1 (9) 2 (8)
Black: African or other 2 (29) 3 (38) 2 (18) 7 (27)
Mixed black/white 1 (14) 1 (13) 0 (0) 2 (8)
Asian/Thai 4 (57) 3 (38) 7 (64) 14 (54)
Other 0 (0) 0 (0) 1 (9) 1 (4)
(b) Pharmacokinetic parameters for lopinavir on once-daily (week 4) and twice-daily (week 0) dosing
n
Once-daily
geometric mean (95% CI)c
Twice-daily
geometric mean (95% CI)c
Once-daily/twice-daily
geometric mean ratio (90% CI)
AUC0–24 (h
Mmg/l)a
Total: 26 160.9 (138.4, 187.0) 223.9 (194.8, 257.4) 0.72 (0.62, 0.83)
Weight:
15 to 25kg 7 172.6 (121.3, 245.7) 232.1 (153.3, 351.4)
>25 to 35kg 8 159.3 (120.6, 210.5) 256.8 (209.3, 315.2)
>35kg 11 155.0 (116.8, 205.6) 198.1 (159.8, 245.5)
Cmax (mg/l)
Total: 26 14.0 (12.7, 15.6) 12.5 (11.1, 14.0) 1.13 (1.00, 1.26)
Weight:
15 to 25kg 7 15.5 (12.4, 19.4) 13.5 (9.8, 18.7)
>25 to 35kg 8 15.0 (12.2, 18.5) 14.1 (11.4, 17.3)
>35kg 11 12.5 (10.7, 14.7) 10.9 (9.3, 12.6)
Clast (mg/l)
Total: 26 1.03 (0.61, 1.75) 5.69 (4.58, 7.07) 0.18 (0.12, 0.27)
Weight:
15 to 25kg 7 0.91 (0.27, 3.07) 4.92 (2.65, 9.16)
>25 to 35kg 8 0.93 (0.38, 2.26) 6.65 (5.22, 8.47)
>35kg 11 1.20 (0.42, 3.44) 5.57 (3.73, 8.32)
Clearance (l/(hMkg))b
Total: 26 0.115 (0.099, 0.134) 0.084 (0.074, 0.095) 1.37 (1.19, 1.57)
Weight:
15 to 25kg 7 0.112 (0.076, 0.165) 0.085 (0.062, 0.117)
>25 to 35kg 8 0.120 (0.091, 0.158) 0.076 (0.062, 0.094)
>35kg 11 0.114 (0.086, 0.150) 0.089 (0.071, 0.113)
Tmax(h)
c
Total: 26 4.0 (2.0, 8.0) 3.5 (0.0, 12.0)
Weight:
15 to 25kg 7 4.0 (2.0, 8.0) 3.8 (0.0, 4.1)
>25 to 35kg 8 4.0 (2.0, 6.0) 2.8 (1.7, 4.0)
>35kg 11 4.0 (2.0, 8.0) 3.4 (1.7, 12.0)
aAUC0–24 for b.i.d. dosing ¼ AUC0–12M2.
bClearance calculated as Cl/F/kg ¼ dose(mg)/[AUC0–24(hMmg/l)Mbody weight (kg)].
cFor Tmax median values (minimum, maximum) are reported.
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groups were represented. The rate of virological rebound,
defined as confirmed viral load at least 50 copies/ml at any
time within 48 weeks, was low in both arms. However,
noninferiority of lopinavir/r q.d. vs. lopinavir/r b.i.d.
dosing, when taken as part of combination ART, was not
demonstrated; 6% more children in the q.d. arm
experienced viral load rebound within the first 48 weeks,
and the upper bound of the CI of 14% was outside the
predetermined noninferiority bound of 12%. This
difference was partially explained by the chance
imbalance between arms in viral rebound which occurred
between screening and baseline. However, even after
adjustment the upper bound of the CI was 11%, only just
within the predefined 12% margin of noninferiority.
No significant safety issues were demonstrated and there
were no differences between arms in development of
resistance mutations.
The within patient pharmacokinetic substudy showed
that administration of lopinavir/r paediatric tablets q.d.
resulted in lower daily exposure to lopinavir and a lower
Clast compared with b.i.d. dosing in the same child. In
adults, higher exposure (AUC0–24 206.5mg.h/ml), but
comparable Cmax (14.8mg/ml) has been observed after
q.d. dosing of 800/200mg lopinavir [21]. Elimination
half-life (t1/2) was comparable with values found in adults:
mean t1/2 (SD) in our study was 6.0 h (3.0 h) for q.d. and
7.7 h (3.0 h) for b.i.d., compared with 6.1 h (2.5 h) and
8.6 h (4.2 h) in adults, respectively [5]. Previous smaller
paediatric studies have reported that the AUC0–24 of
lopinavir after q.d. dosing of lopinavir/r using various
formulations (solution, soft-gel capsules and tablets) lies
between 150 and 215 hmg/l, and Clast between 1.6 and
5.8mg/l [10–12,22–25]. In our larger study, theAUCwas
at the lower endof this range andClast below it. This cannot
be explained by lower dose, as the median lopinavir dose
received by children in the pharmacokinetic study was
19.0mg/kg or 537mg/m2 q.d., which is comparable or
higher than the doses received by children in the other
studies. In addition, exposure to lopinavir from tablets in
adults was shown to be significantly higher than from soft-
gel capsules, although the 90% CI of the GMR was
reported to be within the bioequivalence range [13].
Additional findings from this trial reflect ‘real life’ dosing,
as not only were formal ‘within-child’ pharmacokinetic
studies undertaken, but also sparse random sampling in all
children attending clinic throughout the 48 weeks. We
demonstrated that more children in the q.d. treatment
group had at least one undetectable (<LLOQ) lopinavir
plasma concentration: 24.4% q.d. vs. 8.0% b.i.d. Further
we observed a pharmacokinetic/pharmacodynamics
relationship, with the overall risk of viral load rebound
being over seven-fold greater among children with at least
one lopinavir concentration <LLOQ, and twice as high
in q.d. vs. b.i.d. children (9.3 vs. 4.6). These findings
together with the results of the within-child pharmaco-
kinetic show that lopinavir is less forgiving when children
are dosed q.d., and thus if children are nonadherent, there
is a higher chance of virological rebound. Despite this
during the trial, nine out of 12 children on q.d. who
rebounded later resuppressed, and seven of the nine
remained on q.d. lopinavir/r. Although drug concen-
tration measurements demonstrated that missed q.d. doses
had a greater risk of viral rebound, reassuringly due to the
relatively high resistance barrier of ritonavir-boosted
lopinavir, development of new mutations remained low,
and similar to b.i.d. dosing.
Both children and carers reported a preference for taking
lopinavir/r q.d., but data from the adherence ques-
tionnaires suggests that a small number of children may
miss more doses on q.d.
In resource-rich countries, other q.d. boosted protease
inhibitor treatments are nowwidely available for children,
but in resource poor situations, which carry the burden of
the epidemic, lopinavir/r remains the mainstay of
paediatric protease inhibitor based therapy (Habiyambere
V, WHO ARV use survey, 2014, personal communi-
cation) [26], and the findings of the trial are particularly
relevant to these settings.
In conclusion, based on the combination of viral load
rebound and pharmacokinetic results in the KONCERT
trial, q.d. lopinavir/r cannot be routinely recommended
as a simplification option for children with suppressed
viral load on b.i.d. lopinavir/r. However, among selected
adherent children for whom regular viral load monitoring
is available, q.d. dosing remains an option, as we have
demonstrated that it is both safe and not associated with
any increased risk of developing resistance mutations.
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